[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of relapsed ovarian cancer * Responded to at least on one line of prior platinum based therapy * Relapsed within platinum resistant interval (≤6months) * Eastern Cooperative Oncology Group (ECOG) performance status of \<2 * Measurable disease defined as a lesion that can be accurately measured in at least one dimension with the longest diameter ≥25mm using conventional techniques * Satisfactory baseline haematologic and organ function: * Haematologic: Absolute neutrophil count \> or = 1.5 X 10\^9/L; Platelets \> or = 100 X 10\^9/L; Haemoglobin \> or = 9g/dL; PT or INR \< or = 1.2 x ULN; PTT \< or = 1.2 x ULN * Hepatic: Bilirubin \< or = 1.5 X ULN; AST or ALT \< or = 2.5 X ULN * Renal: Serum creatinine \< or = 1.5 mg/dL; Or if \>1.5 mg/dL, calculated creatinine clearance \> or = 50mL/min; UPC \<1 Exclusion Criteria: * Poorly controlled hypertension \[defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg\]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be \<140/90 mmHg in order for a subject to be eligible for the study. * Treatment with any of the following anti-cancer therapies: * radiation therapy 28 days prior to the first dose of pazopanib OR * surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR * chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib * Treatment with anti-angiogenic therapy * Presence of gross ascites * Clinically significant peripheral neuropathy * Females of childbearing potential who are unwilling to avoid pregnancy, for the duration of the study